Mirabegron in female patients with overactive bladder syndrome: What's new? A systematic review and meta-analysis.
Detrusor overactivity
Sexual function
Urodynamic study
β3-adrenoceptor
Journal
European journal of obstetrics, gynecology, and reproductive biology
ISSN: 1872-7654
Titre abrégé: Eur J Obstet Gynecol Reprod Biol
Pays: Ireland
ID NLM: 0375672
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
13
03
2020
revised:
07
05
2020
accepted:
11
05
2020
pubmed:
2
6
2020
medline:
15
5
2021
entrez:
2
6
2020
Statut:
ppublish
Résumé
Reviews assessing mirabegron's safety and efficacy, synthesize data from both genders, without providing specific details for female patients with OAB. The aim of this study is to qualitatively and quantitatively synthesize data evaluating mirabegron's use on female patients with OAB. PubMed/Scopus/Cochrane library/Web of Knowledge were searched for full texted, published in English-language and in peer-reviewed journals, up to November 2019, using the keyword "mirabegron".Jadad score modified by adding allocation concealment, MINORS and RoB were used for the Methodological quality and risk of bias assessment. Twenty-one studies were included in this review;7 RCTs, 3 non-RCTs and 11 observational studies. Controlled trials were of unclear (75%), high (12.5%) or serious risk (12.5%) of bias. Twelve weeks of mirabegron use resulted in significant decrease of urgency, frequency, nocturia and UUI by 1.3-2.2,2.04-2.33,0.42-0.5 and 0.9-1.04 episodes/24 h, respectively. Quality of life and sexual health was improved significantly. Sexual dysfunction decreased from 98% (84/85) at baseline, to 60% (51/85) after 12-weeks of mirabegron (p-value < 0.001). Mirabegron had the same efficacy as anticholinergics in improving all OAB symptoms but with fewer adverse events. Hypertension and antimuscarinics' effects (i.e dry mouth, constipation) had an incidence of 2% (28/1221) and 1.9% (23/1221) when mirabegron was administered, respectively. Mirabegron is a safe and effective alternative therapy for females with OAB. However, there is a paucity of high-quality RCTs, with large sample sizes, long-term follow-up focusing on mirabegron's comparison to other therapies, quality of life and sexual health of female patients with OAB.
Identifiants
pubmed: 32480182
pii: S0301-2115(20)30269-4
doi: 10.1016/j.ejogrb.2020.05.018
pii:
doi:
Substances chimiques
Acetanilides
0
Muscarinic Antagonists
0
Thiazoles
0
Urological Agents
0
mirabegron
MVR3JL3B2V
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
73-82Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Stavros Athanasiou has had speakers fee from Pierre Fabre and support to international meeting from Astellas; Stefano Salvatore has had speakers fee from Astellas and Pierre Fabre; Maurizio Serati has had speakers fee from Pierre Fabre. The other authors report no potential conflicts of interest.